8-K: TriSalus Life Sciences Reports 42% Revenue Growth in Q1 2025, Updates 2025 Guidance

TriSalus Life Sciences announces strong Q1 2025 results with 42% revenue growth and updates its 2025 guidance to reflect strategic investments.

Summary

• TriSalus Life Sciences reported a 42% increase in revenue for the first quarter of 2025, reaching $9.2 million.
• The company is expanding its commercial footprint and investing in new applications for its TriNav technology.
• A private placement raised $22 million in gross proceeds to support continued growth.
• The company is confirming revenue guidance of at least 50% growth for 2025.
• Due to increased investment in strategic priorities, TriSalus no longer expects to be adjusted EBITDA-positive or cash flow-positive in 2025.
• Operating losses for Q1 2025 were $7.3 million, an improvement from $11.7 million in the same period of 2024.
• Net losses available to common stockholders were $10.4 million for Q1 2025, compared to $13.2 million for Q1 2024.
• Adjusted EBITDA losses were $5.5 million for Q1 2025, compared to $10.4 million for Q1 2024.
• Cash and cash equivalents totaled $13.0 million as of March 31, 2025.
• The company expects to be adjusted EBITDA positive in the first half of 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Strong revenue growth and strategic investments are positive, but the revised EBITDA guidance and continued losses temper the outlook.

Positives

• Revenue increased by 42% year-over-year in Q1 2025, reaching $9.2 million.
• The company secured $22 million in gross proceeds via a private placement.
• Operating losses decreased from $11.7 million in Q1 2024 to $7.3 million in Q1 2025.
• Adjusted EBITDA losses decreased from $10.4 million in Q1 2024 to $5.5 million in Q1 2025.
• The company reached an agreement with 55% of preferred shareholders to simplify the capital structure.
• The company expects to be adjusted EBITDA positive in the first half of 2026.

Negatives

• The company no longer expects to be adjusted EBITDA-positive or cash flow-positive in 2025 due to increased strategic investments.
• Net losses available to common stockholders were $10.4 million for Q1 2025.
• Gross margins slightly decreased from 85% in Q1 2024 to 84% in Q1 2025 due to decreased production from clean room expansion.

Risks

• The company's future clinical results may not be consistent with patient data generated during the company's clinical trials.
• The company's ability to remain in compliance with all its obligations under the credit facility to avoid an event of default is a risk.
• The company will continue to raise capital through the issuance and sale of its equity securities to fund its operations.
• The company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility.
• The company will not become profitable on its expected timeline, if at all.
• The reported financial results will differ from the estimates provided in this press release.
• Changes in expected or existing competition or market conditions could impact results.
• Changes in the regulatory environment could impact results.
• Unexpected litigation or other disputes could impact results.
• Unexpected expensed costs could impact results.

Future Outlook

TriSalus is confirming its revenue guidance of at least 50% growth for 2025 but no longer expects to be adjusted EBITDA-positive or cash flow-positive in 2025 due to strategic investments. The company expects to be adjusted EBITDA positive in the first half of 2026.

Management Comments

• Our strong first quarter performance reflects the growing impact of our PEDD platform across a variety of solid tumor indications, said Mary Szela, President and CEO of TriSalus.
• Following our recent private placement, we have made the strategic decision to further invest in our sales force expansion and clinical registries in new applications of our technology.
• We believe this growth-oriented strategy balances financial discipline with bold investments designed to drive long-term value creation.

Industry Context

TriSalus is operating in the competitive oncology space, focusing on innovative drug delivery technologies and immunotherapies. The company's focus on liver and pancreatic tumors aligns with the growing need for effective treatments in these areas.

Comparison to Industry Standards

• Comparing TriSalus's 42% revenue growth to other medical technology companies in the oncology space, such as Boston Scientific or Medtronic, requires considering their diverse product portfolios and market capitalization.
• While direct comparisons are challenging, TriSalus's growth rate suggests a strong market adoption of its TriNav platform.
• The company's focus on Pressure-Enabled Drug Delivery (PEDD) sets it apart from competitors primarily focused on systemic therapies.
• The adjusted EBITDA losses reflect the investment phase the company is in, which is common for growth-oriented medical technology companies.

Stakeholder Impact

• Shareholders will see continued investment in growth, but profitability is pushed further out.
• Employees may benefit from the expansion of the commercial organization.
• Patients may benefit from the development of new clinical applications for the TriNav platform.
• Suppliers may see increased demand for TriNav systems.

Next Steps

• The company will continue to expand its commercial organization and develop new clinical applications for its core technology.
• TriSalus will explore partnership opportunities for the development of Nelitolimod.
• The company will host a conference call and webcast to discuss its financial results.

Key Dates

Keywords

TriSalus, Life Sciences, Financial Results, Q1 2025, Revenue Growth, PEDD, TriNav, Nelitolimod, Oncology, EBITDA, Guidance